Evidence map›Paper›PMID 40836233›Full record

ReviewBMC urology2025

Diagnosis and management of TFE3-rearranged renal cell carcinoma: case report and literature review.

Yongxin Zhang, Junxin Shen, Jinfeng Wu, Hongxing Huang, Fengjiao Meng, Runqiang Yuan, Yangbai Lu

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongxin Zhang *Department of MR, Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
Junxin Shen *Department of First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong, China.
Jinfeng Wu *Department of First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong, China.
Hongxing HuangDepartment of First Clinical Medical College, Guangdong Medical University, Zhanjiang, Guangdong, China.
Fengjiao MengDepartment of Pathology, Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
Runqiang YuanDepartment of Urology, Zhongshan City People's Hospital, Zhongshan, Guangdong, 528403, China. yuanrunqiang@yeah.net.
Yangbai LuDepartment of Urology, Zhongshan City People's Hospital, Zhongshan, Guangdong, 528403, China. luyangbai2020@163.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2022A1515220032Guangdong Medical Science and Technology Research Foundation B2023195Science and Technology Project of Zhongshan City 2020B1073Zhongshan city people's hospital Major Project of Scientific Research Foundation BG20228249Zhongshan City People's Hospital Outstanding Youth Project SG2023106
6 · The paper itself

Abstract

backgroundTFE3-rearranged renal cell carcinoma is a rare malignancy with distinctive morphological and immunological characteristics. Although it can manifest in individuals of any age, its occurrence in adults is exceedingly uncommon, comprising only 1.5% of adult renal cell carcinomas. The disease typically presents with a benign course in pediatric patients, yet in adults, it often progresses rapidly and aggressively. CASE PRESENTATION: Herein, we present a case of a 35-year-old female diagnosed with TFE3-rearranged renal cell carcinoma, who was initially asymptomatic. Imaging studies revealed a solid renal mass in the left kidney without signs of metastasis. Initially misdiagnosed as a vascular smooth muscle lipoma, the patient underwent laparoscopic partial nephrectomy. Subsequent histopathological and molecular analyses validated the diagnosis of TFE3-rearranged renal cell carcinoma. The patient demonstrated favorable short-term outcomes after early laparoscopic intervention, with no evidence of tumor recurrence or metastasis at both the 4-month and 15-month follow-ups.

conclusionsThis case serves as a valuable resource for oncologists involved in the diagnosis and management of TFE3-rearranged renal cell carcinoma.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCarcinoma, Renal CellGene RearrangementKidney NeoplasmsAdultFemaleHumansNephrectomyBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsTFE3 protein, humanImmunohistochemistryPathologyPrognosisRenal cell carcinomaTFE3

Identifiers

PMID40836233
PMCPMC12369123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.